CD19 and acute lymphoblastic leukemia: Patients with B-ALL have several options available after relapse thanks to the development of the CD19 × CD3 bispecific T-cell engager blinatumomab37, the anti-CD22 antibody-drug conjugate inotuzumab ozogamicin38, or the chimeric antigen receptor (CAR)-T-cell therapy39.